A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naive and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Abiraterone acetate (Primary) ; Dexamethasone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Janssen
- 29 Mar 2021 Results assessing Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer published in the Annals of Oncology
- 04 Jun 2019 Results assessing association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone acetate plus prednisone/dexamethasone, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 22 Jun 2018 Status changed from active, no longer recruiting to completed.